<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Bradykinetic movement disorders in children
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Bradykinetic movement disorders in children
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Bradykinetic movement disorders in children
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joseph Jankovic, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marc C Patterson, MD, FRACP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Helen V Firth, DM, FRCP, FMedSci
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Glenn A Tung, MD, FACR
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            April F Eichler, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 19, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Movement disorders are characterized by either reduced or slow (bradykinetic) or excessive (hyperkinetic) activity. Bradykinetic movement disorders frequently are accompanied by rigidity, postural instability, and loss of automatic associated movements. Diagnosis of the specific condition depends primarily upon careful observation of the clinical features [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Bradykinetic disorders are reviewed here. Many such disorders, mostly rare, exist and only four are discussed here:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Parkinson disease (PD)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Wilson disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Huntington disease (HD)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neurodegeneration with brain iron accumulation (NBIA)
        </p>
        <p>
        </p>
        <p>
         Hyperkinetic disorders are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6232.html" rel="external">
          "Hyperkinetic movement disorders in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          ANATOMY OF THE BASAL GANGLIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         A brief review of the anatomy of the basal ganglia is appropriate because this site is involved in many of the bradykinetic disorders. The basal ganglia regulate the initiation, scaling, and control of the amplitude and direction of movement. Movement disorders can result from biochemical or structural abnormalities in these structures.
        </p>
        <p>
         The basal ganglia are a complex of deep nuclei that consist of the corpus striatum, globus pallidus, and substantia nigra. The corpus striatum, which includes the caudate nucleus and the putamen, receives input from the cerebral cortex and the thalamus and, in turn, projects to the globus pallidus.
        </p>
        <p>
         The substantia nigra is divided into the dopamine-rich pars compacta and the less dense pars reticularis. The pars reticularis is similar histologically and chemically to the medial segment of the globus pallidus, and both project via the thalamus to the premotor and motor cortex. The substantia nigra pars compacta gives rise to the nigral-striatal pathway, which is the main dopaminergic tract.
        </p>
        <p>
         The output of the basal ganglia projects by way of the thalamus to the cerebral cortex and then to the pyramidal system. Basal ganglia output is sometimes referred to as the extrapyramidal system, a term now less commonly used, because it was once thought to be in parallel with the pyramidal system. Integration of the basal ganglia with the cortex facilitates motor control.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PARKINSON DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bradykinetic movement disorders are characterized by slowness of movement and consist predominantly of conditions with features of parkinsonism, of which Parkinson disease (PD) is the most prominent example  (
         <a class="graphic graphic_table graphicRef80669" href="/z/d/graphic/80669.html" rel="external">
          table 1
         </a>
         ). Other characteristic motor findings of PD include tremor at rest, rigidity, and gait disturbance. In addition, nonmotor symptoms are also increasingly recognized components of PD. These include olfactory deficit; behavioral, cognitive, and sleep deficits; and dysautonomia. (See
         <a class="medical medical_review" href="/z/d/html/4903.html" rel="external">
          "Clinical manifestations of Parkinson disease"
         </a>
         .)
        </p>
        <p>
         PD typically presents in middle and late life. However, early-onset disease can occur before age 40 years, and a juvenile form presents before age 21 [
         <a href="#rid2">
          2
         </a>
         ]. Dystonia (often involving the legs), levodopa-induced dyskinesia, and levodopa-related motor fluctuations (eg, "wearing off" and "on-off" responses several hours following a dose) are common in the young-onset and juvenile forms of PD [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6232.html" rel="external">
          "Hyperkinetic movement disorders in children", section on 'Dystonia'
         </a>
         .)
        </p>
        <p>
         Most cases of PD are sporadic, but genetic loci (
         <em>
          PARK1
         </em>
         through
         <em>
          PARK23
         </em>
         ) have been associated with autosomal dominant or recessive PD or parkinsonism [
         <a href="#rid2">
          2
         </a>
         ]. The genetic causes of PD are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4906.html" rel="external">
          "Epidemiology, pathogenesis, and genetics of Parkinson disease", section on 'Genetics'
         </a>
         .)
        </p>
        <p>
         The diagnosis of juvenile parkinsonism is based on clinical signs beginning before the age of 21 years, while young-onset parkinsonism refers to cases presenting between 21 and 40 years of age [
         <a href="#rid3">
          3,4
         </a>
         ]. Patients have gradual onset of slowness of movement, tremors in the hands or legs (but not the head), rigidity of muscles, shuffling gait, and postural instability. Other signs include lack of facial expression (hypomimia), drooling, dysarthria, and dystonia (involuntary spasms and abnormal postures of hands and feet).
        </p>
        <p>
         Levodopa is the most effective drug in the treatment of PD [
         <a href="#rid5">
          5
         </a>
         ]. However, most patients develop abnormal involuntary movements (dyskinesia) and unpredictable fluctuations in motor functioning within three years of treatment. Patients with onset before age 40 years are most likely to be affected. As a result, particularly in young patients, therapy is often initiated with other drugs that will control the symptoms and delay the need for levodopa. They include anticholinergic drugs (eg,
         <a class="drug drug_pediatric" data-topicid="12863" href="/z/d/drug information/12863.html" rel="external">
          trihexyphenidyl
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13387" href="/z/d/drug information/13387.html" rel="external">
          amantadine
         </a>
         ) and dopamine agonists (eg,
         <a class="drug drug_general" data-topicid="9560" href="/z/d/drug information/9560.html" rel="external">
          pramipexole
         </a>
         and
         <a class="drug drug_general" data-topicid="10246" href="/z/d/drug information/10246.html" rel="external">
          ropinirole
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4896.html" rel="external">
          "Initial pharmacologic treatment of Parkinson disease"
         </a>
         .)
        </p>
        <p>
         Complications of levodopa are managed by adjusting the dose and frequency of administration. If these changes do not alleviate symptoms, surgical treatment, such as high-frequency stimulation of the subthalamic nucleus or globus pallidus, is considered.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          WILSON DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Wilson disease is a treatable cause of juvenile parkinsonism, dystonia, tremor, and other movement disorders. This rare disorder has an estimated prevalence of 30 per million.
        </p>
        <p>
         Wilson disease is an autosomal recessive defect of cellular copper export. The major abnormality is reduced biliary excretion of copper that leads to its accumulation, initially in the liver and then in other tissues, particularly the brain. Tissue copper deposition causes a multitude of signs and symptoms that reflect hepatic, neurologic, hematologic, and renal impairment. The incorporation of copper into ceruloplasmin is also impaired.
        </p>
        <p>
         Clinical aspects of Wilson disease are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3626.html" rel="external">
          "Wilson disease: Epidemiology and pathogenesis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83837.html" rel="external">
          "Wilson disease: Clinical manifestations, diagnosis, and natural history"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3591.html" rel="external">
          "Wilson disease: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          JUVENILE HUNTINGTON DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Huntington disease (HD) typically presents during the fourth and fifth decades of life; however, onset occurs during childhood or adolescence in approximately 5 to 7 percent of affected patients.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Genetics
         </span>
         <span class="headingEndMark">
          —
         </span>
         The genetics and pathogenesis of HD are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6182.html" rel="external">
          "Huntington disease: Genetics and pathogenesis"
         </a>
         .)
        </p>
        <p>
         Reviewed briefly, HD is transmitted as an autosomal dominant trait with the affected gene being on the short arm of chromosome 4. Juvenile-onset disease shows a major transmitting parent effect, as approximately 80 percent of symptomatic patients inherit the mutant HD gene from their father [
         <a href="#rid6">
          6,7
         </a>
         ]. The high number of cellular divisions that occur during spermatogenesis likely accounts for the pronounced paternal-repeat instability.
        </p>
        <p>
         HD is one of a number of disorders that are associated with expansion of unstable trinucleotide (cytosine-adenine-guanine [CAG]) repeats that encode for polyglutamine tracts in the protein products. There is mounting evidence that fragments of the huntingtin protein containing expanded polyglutamine tracts may be neurotoxic. The greater the number of CAG repeats on expanded alleles, the earlier the age of onset and more severe the disease [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         Demonstration of more than 36 CAG repeats in one of the alleles in the HD gene confirms the diagnosis of HD. Alleles with 27 to 35 CAG repeats are termed "intermediate alleles." An individual with an allele in this range is not at risk of developing symptoms of HD but may be at risk of having a child with an allele in the disease range. Juvenile forms are associated with alleles containing more than 60 to 70 CAG repeats and, in some patients, more than 100 repeats.
        </p>
        <p>
         The inverse relationship between age of onset and number of CAG repeats was confirmed in a Dutch cohort of 755 affected patients [
         <a href="#rid9">
          9
         </a>
         ]. The correlation was stronger for paternal than maternal inheritance.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Clinical features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with juvenile HD develop dystonia, ataxia, and seizures. Most of them have the akinetic-rigid parkinsonian syndrome termed the "Westphal variant." Only a minority have the classic feature of chorea seen in adults.
        </p>
        <p>
         One retrospective study reported longitudinal data for 36 patients with juvenile HD and 197 with adult-onset HD [
         <a href="#rid8">
          8
         </a>
         ]. The study examined presentation, progression, and survival for two subgroups of juvenile HD defined by CAG repeat length [
         <a href="#rid8">
          8
         </a>
         ]. The high-expansion subgroup (n = 10; median CAG repeat length of 86) had a younger median age of symptom onset than the low-expansion subgroup (n = 26; median CAG repeat length of 61). Dystonia and parkinsonism were the main motor symptoms at onset in both subgroups. With disease progression, severe gait impairment, seizures, and developmental delay were more common in the high-expansion subgroup, while chorea developed only in the low-expansion subgroup. Overall, patients with juvenile HD had more rapidly progressive disease than those with adult-onset HD. Of 121 deceased patients (17 with juvenile and 104 with adult-onset HD), median survival from study enrollment was shorter in the juvenile HD cohort compared with the adult-onset HD cohort (hazard ratio 2.18, 95% CI 1.08-4.40).
        </p>
        <p>
         Biochemical changes observed in the brains of adults with HD may explain the neurologic features. Glutamic acid decarboxylase activity is reduced, especially in the corpus striatum, substantia nigra, and other basal ganglia. By contrast, thyrotropin-releasing hormone, neurotensin, somatostatin, and neuropeptide Y are increased in the corpus striatum. The depletion of gamma-aminobutyric acid in the corpus striatum may result in disinhibition of the nigral-striatal pathway. Coupled with the accumulation of somatostatin, the net result may be the release of striatal dopamine, which results in chorea.
        </p>
        <p>
         The pattern of brain abnormality depends upon the age of onset. The characteristic pathologic change in adults with HD is diffuse, marked atrophy of the neostriatum that may be worse in the caudate than in the putamen. The changes are more dramatic in early-onset HD  (
         <a class="graphic graphic_diagnosticimage graphicRef142454" href="/z/d/graphic/142454.html" rel="external">
          image 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/6182.html" rel="external">
          "Huntington disease: Genetics and pathogenesis", section on 'Neuropathology'
         </a>
         .)
        </p>
        <p>
         The reasons for the selective vulnerability of the medium spiny neurons in the striatum is not known, but some insight may be gained from the study of Rhes (Ras homolog enriched in striatum), a small guanine nucleotide-binding protein that is selectively localized to the striatum and to a much lesser extent in the cortex, but not in the cerebellum. Rhes binds physiologically to mutated huntingtin and leads to selective cytotoxicity. (See
         <a class="medical medical_review" href="/z/d/html/6182.html" rel="external">
          "Huntington disease: Genetics and pathogenesis", section on 'Rhes'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Management
         </span>
         <span class="headingEndMark">
          —
         </span>
         No cure or disease-modifying treatment is currently available for HD [
         <a href="#rid10">
          10
         </a>
         ]. Therapy is focused on symptom management and supportive care in order to optimize quality of life. (See
         <a class="medical medical_review" href="/z/d/html/4902.html" rel="external">
          "Huntington disease: Management"
         </a>
         .)
        </p>
        <p>
         The impact of chorea in patients with HD should be carefully assessed to determine whether any specific treatment is necessary, since it may not be a debilitating or bothersome symptom, particularly in early stages. Pharmacologic treatment of chorea may worsen other aspects of HD, including parkinsonism, cognition, and mood. When chorea does become severe, padded reclining chairs and bed padding are recommended to reduce the risk of injury.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9476" href="/z/d/drug information/9476.html" rel="external">
          Tetrabenazine
         </a>
         , a dopamine depleting agent that acts by inhibiting presynaptic vesicular monoamine transporter type 2 (VMAT2), can be useful for controlling chorea in patients with HD. Compared with the typical neuroleptics, one of the advantages of tetrabenazine is that it does not cause tardive dyskinesia. However, tetrabenazine treatment was associated with significantly more adverse events than placebo treatment in randomized trials. Dose-limiting symptoms with tetrabenazine included sedation, akathisia, parkinsonism, and depressed mood; these generally resolved with dose adjustments. Two other VMAT2 inhibitors approved by the US Food and Drug Administration (FDA) are
         <a class="drug drug_general" data-topicid="112590" href="/z/d/drug information/112590.html" rel="external">
          deutetrabenazine
         </a>
         (for chorea associated with HD and for tardive dyskinesia in adults) and
         <a class="drug drug_general" data-topicid="112668" href="/z/d/drug information/112668.html" rel="external">
          valbenazine
         </a>
         (for tardive dyskinesia in adults) [
         <a href="#rid11">
          11
         </a>
         ]. Both have a longer duration of action and improved side effect profile compared with tetrabenazine. (See
         <a class="medical medical_review" href="/z/d/html/4902.html" rel="external">
          "Huntington disease: Management", section on 'Tetrabenazine'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4902.html" rel="external">
          "Huntington disease: Management", section on 'Deutetrabenazine'
         </a>
         .)
        </p>
        <p>
         For patients with HD who have moderately severe chorea that does not respond to nonpharmacologic intervention, we suggest initial treatment with
         <a class="drug drug_general" data-topicid="9476" href="/z/d/drug information/9476.html" rel="external">
          tetrabenazine
         </a>
         or
         <a class="drug drug_general" data-topicid="112590" href="/z/d/drug information/112590.html" rel="external">
          deutetrabenazine
         </a>
         rather than dopamine receptor blocking drugs (neuroleptics) [
         <a href="#rid11">
          11,12
         </a>
         ]. For chorea that does not respond to VMAT2 inhibitors, additional treatment options include atypical and typical neuroleptics. Beyond these, alternatives include
         <a class="drug drug_pediatric" data-topicid="13387" href="/z/d/drug information/13387.html" rel="external">
          amantadine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12910" href="/z/d/drug information/12910.html" rel="external">
          levetiracetam
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="12851" href="/z/d/drug information/12851.html" rel="external">
          topiramate
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/4902.html" rel="external">
          "Huntington disease: Management", section on 'Management of chorea'
         </a>
         .)
        </p>
        <p>
         Levodopa may provide symptomatic relief of the parkinsonian features of childhood HD.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Future directions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many different potential therapies have shown some promise in animal models of HD, and some are being evaluated in early clinical trials [
         <a href="#rid13">
          13-15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4902.html" rel="external">
          "Huntington disease: Management", section on 'Investigational therapies'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          NEURODEGENERATION WITH BRAIN IRON ACCUMULATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neurodegeneration with brain iron accumulation (NBIA) is a rare progressive neurodegenerative syndrome that causes parkinsonism, dystonia, cognitive decline, and other neurologic deficits. NBIA is now considered a spectrum of phenotypically overlapping disorders, with several subtypes defined by differences at the molecular genetic level [
         <a href="#rid16">
          16-20
         </a>
         ]. These subtypes are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pantothenate kinase-associated neurodegeneration (PKAN), formerly known as Hallervorden-Spatz disease, caused by pathogenic variants in the gene encoding pantothenate kinase 2 (
         <em>
          PANK2
         </em>
         ) [
         <a href="#rid21">
          21,22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infantile neuroaxonal dystrophy (INAD), an autosomal recessive disorder, caused by pathogenic variants in the phospholipase A2 group VI (
         <em>
          PLA2G6
         </em>
         ) gene. (See
         <a class="medical medical_review" href="/z/d/html/6226.html" rel="external">
          "Neuropathies associated with hereditary disorders", section on 'Infantile neuroaxonal dystrophy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mitochondrial membrane protein-associated neurodegeneration (MPAN), caused by homozygous or compound heterozygous pathogenic variants in the chromosome 19 open reading frame 12 (
         <em>
          C19orf12
         </em>
         ) gene [
         <a href="#rid23">
          23-27
         </a>
         ]. Families carrying heterozygous pathogenic variants, inherited in an autosomal dominant pattern from a mosaic parent, have also been described, along with a late-onset phenotype in individuals with mosaicism [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beta-propeller protein-associated neurodegeneration (BPAN) [
         <a href="#rid28">
          28,29
         </a>
         ], also known as static encephalopathy of childhood with neurodegeneration in adulthood (SENDA) [
         <a href="#rid17">
          17,30
         </a>
         ], caused by de novo pathogenic variants in the WD repeat domain 45 (
         <em>
          WDR45
         </em>
         ) gene [
         <a href="#rid29">
          29,31
         </a>
         ]. This disorder presents with global developmental delay in childhood followed by deterioration in early adulthood with progressive dystonia, parkinsonism, and cognitive decline [
         <a href="#rid28">
          28
         </a>
         ]. Although
         <em>
          WDR45
         </em>
         is located on Xp11.23 and undergoes inactivation, the clinical features of this form of NBIA do not follow a pattern typical of an X-linked disorder [
         <a href="#rid29">
          29
         </a>
         ]. The phenotype of affected males was indistinguishable from that of females, with a striking uniformity of the clinical features and natural history of the disease in all 20 study participants (17 females and 3 males).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fatty acid hydroxylase-associated neurodegeneration (FAHN), a childhood-onset disorder characterized by gait impairment, spastic paraparesis, ataxia, and dystonia caused by pathogenic variants in the fatty acid 2-hydroxylase (
         <em>
          FA2H
         </em>
         ) gene [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Kufor-Rakeb syndrome, an autosomal recessive condition caused by pathogenic variants in the ATPase cation transporting 13A2 (
         <em>
          ATP13A2
         </em>
         ) gene [
         <a href="#rid33">
          33-35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neuroferritinopathy, an adult-onset autosomal dominant basal ganglia disease characterized by variable symptoms that include parkinsonism, chorea, and dystonia [
         <a href="#rid36">
          36
         </a>
         ]. The disorder is caused by pathogenic variants in the ferritin light chain (
         <em>
          FTL
         </em>
         ) gene [
         <a href="#rid37">
          37
         </a>
         ]. Serum ferritin levels are normal or low.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aceruloplasminemia, an adult-onset autosomal recessive disorder caused by pathogenic variants in the ceruloplasmin gene and characterized by ceruloplasmin deficiency, diabetes, dementia, parkinsonism, chorea, and ataxia [
         <a href="#rid38">
          38,39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Woodhouse-Sakati syndrome [
         <a href="#rid40">
          40
         </a>
         ], a progressive extrapyramidal syndrome characterized by dystonia, dysarthria, cognitive decline, and endocrine abnormalities such as hypogonadism, alopecia, and diabetes mellitus. It follows an autosomal recessive inheritance pattern and is caused by biallelic pathogenic variants in the DDB1 and CUL4 associated factor 17 (
         <em>
          DCAF17
         </em>
         ) gene [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         NBIA of unknown cause.
        </p>
        <p>
        </p>
        <p>
         Of these, the most common genetic types of NBIA, in descending order, are PKAN, INAD, MPAN, and BPAN [
         <a href="#rid19">
          19,42
         </a>
         ]. The other genetic types of NBIA listed above appear to be rare. Nevertheless, idiopathic NBIA and the minor genetic forms account for approximately 38 percent of cases.
        </p>
        <p>
         The following discussion will focus on NBIA of childhood onset, particularly PKAN. INAD is reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/6226.html" rel="external">
          "Neuropathies associated with hereditary disorders", section on 'Infantile neuroaxonal dystrophy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Clinical features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with NBIA have posture and gait abnormalities, bradykinesia, rigidity, and other parkinsonian features, including tremor. Affected patients may also have hyperkinetic movement disorders, such as dystonia and choreoathetosis, as well as progressive dysarthria, dementia, ataxia, spasticity, epilepsy, optic atrophy, and retinitis pigmentosa.
        </p>
        <p>
         As noted above, many patients with NBIA have pathogenic variants in the
         <em>
          PANK2
         </em>
         gene and are said to have PKAN [
         <a href="#rid19">
          19,21,43,44
         </a>
         ]. PKAN is inherited in an autosomal recessive pattern, but NBIA also occurs sporadically, and some phenotypically similar cases appear to be transmitted in an autosomal dominant fashion.
        </p>
        <p>
         The relationship between genotype and phenotype was evaluated in a study of 123 patients from 98 families with NBIA [
         <a href="#rid44">
          44
         </a>
         ]. Two variants were distinguished:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Classic disease with early onset (typically in the first decade of life) and rapid progression
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Atypical disease with later onset (usually in the second or third decade of life) and slow progression
        </p>
        <p>
        </p>
        <p>
         All patients with classic disease and one-third of those with atypical disease had
         <em>
          PANK2
         </em>
         pathogenic variants [
         <a href="#rid44">
          44
         </a>
         ]. In this series, abnormalities in classic NBIA were noted with the following frequencies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Movement disorders including dystonia, dysarthria, rigidity, and choreoathetosis – 98 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Retinopathy – 68 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cognitive decline – 29 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Corticospinal tract involvement, including spasticity, hyperreflexia, and extensor toe signs – 25 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Few patients had optic atrophy (3 percent) and none had seizures
        </p>
        <p>
        </p>
        <p>
         Prominent speech-related and psychiatric symptoms were common in patients with atypical disease and
         <em>
          PANK2
         </em>
         pathogenic variants [
         <a href="#rid44">
          44
         </a>
         ]. By contrast, these symptoms were unusual in those with atypical disease without
         <em>
          PANK2
         </em>
         variants and in those with classic disease. Limited retrospective data suggest that action-induced dystonic opisthotonus (ie, extensor truncal dystonia) may be a common manifestation of NBIA in patients with
         <em>
          PANK2
         </em>
         and
         <em>
          PLA2G6
         </em>
         pathogenic variants [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Neuroimaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many patients with
         <em>
          PANK2
         </em>
         pathogenic variants, whether classic or atypical, have the characteristic radiologic sign known as "eye of the tiger" on brain magnetic resonance imaging (MRI). On T2-weighted MRI, there is marked hypointensity in the globus pallidus that completely surrounds a central hyperintense focus in the anteromedial globus pallidus  (
         <a class="graphic graphic_diagnosticimage graphicRef142453" href="/z/d/graphic/142453.html" rel="external">
          image 2
         </a>
         ). The hypointensity correlates with excess iron deposition, and the hyperintense center correlates with neuronal loss with gliosis, vacuolization, and water accumulation [
         <a href="#rid44">
          44
         </a>
         ]. However, in rare cases of genetically confirmed juvenile-onset
         <em>
          PANK2
         </em>
         , the "eye of the tiger" sign may be absent initially, only to appear later with the onset of motor impairment [
         <a href="#rid46">
          46
         </a>
         ]. In addition, not all cases with "eye of the tiger" sign are due to
         <em>
          PANK2
         </em>
         .
        </p>
        <p>
         In addition to iron distribution within the globus pallidus and substantia nigra, other typical MRI features vary according to the type of NBIA [
         <a href="#rid19">
          19,42,47
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         PKAN: "Eye of the tiger" sign  (
         <a class="graphic graphic_diagnosticimage graphicRef142453" href="/z/d/graphic/142453.html" rel="external">
          image 2
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infantile neuroaxonal dystrophy (INAD): Cerebellar atrophy; some cases lack iron deposition
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mitochondrial membrane protein-associated neurodegeneration (MPAN): Cerebellar and cortical atrophy and T2-weighted hyperintense streaking between the globus pallidus interna and externa
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beta-propeller protein-associated neurodegeneration (BPAN): T1-weighted signal hyperintensity with a central band of hypointensity within the substantia nigra
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of NBIA is based upon clinical features. The diagnosis of PKAN is suspected when an MRI scan shows a central focus of increased T2 signal intensity surrounded by a zone of decreased signal in the region of the globus pallidus ("eye of the tiger" sign) [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         Genetic sequence analysis for
         <em>
          PANK2
         </em>
         pathogenic variants is recommended by some experts to confirm the diagnosis in those with suspected NBIA and the "eye of the tiger" MRI sign [
         <a href="#rid20">
          20
         </a>
         ]. Options include single gene testing, when clinical features point strongly a specific NBIA type, or screening by gene panel, which includes multiple genes known to be associated with NBIA [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Pathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Increased iron uptake is confirmed by postmortem examination, which reveals the characteristic pigmentary degeneration of the basal ganglia, particularly the internal segment of the globus pallidus and the zona reticularis of the substantia nigra. The pigmentary changes result from marked iron accumulation in these areas [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         The mechanism by which basal ganglia iron uptake is increased in NBIA is not well understood. Systemic and cerebrospinal fluid iron levels, as well as plasma ferritin, transferrin, and ceruloplasmin, are all normal [
         <a href="#rid22">
          22
         </a>
         ]. Furthermore, disorders of systemic iron overload, such as hemochromatosis, are not associated with increased brain iron.
        </p>
        <p>
         Marked neuroaxonal degeneration with the formation of ubiquitinated deposits and spheroids is another distinctive pathologic feature of PKAN [
         <a href="#rid48">
          48
         </a>
         ]. These glycoprotein-containing axonal swellings have been attributed to abnormal lipid membrane peroxidation. It may result from chelation of ferrous iron caused by increased cysteine (demonstrated in one patient with NBIA), leading to the accelerated generation of free hydroxyl radicals in the presence of non-protein-bound iron.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of NBIA, including iron chelation with
         <a class="drug drug_pediatric" data-topicid="13208" href="/z/d/drug information/13208.html" rel="external">
          deferoxamine
         </a>
         and antioxidant therapy, is ineffective. A small randomized controlled trial of patients with PKAN found that treatment with the iron chelator
         <a class="drug drug_pediatric" data-topicid="131933" href="/z/d/drug information/131933.html" rel="external">
          deferiprone
         </a>
         lowered iron content in the basal ganglia (measured by MRI) compared with placebo [
         <a href="#rid49">
          49
         </a>
         ]. However, deferiprone treatment led to only a slight trend towards slowing disease progression, which did not reach statistical significance. A randomized trial of fosmetpantotenate, developed to reverse the biochemical defect in PKAN, found no clinical benefit [
         <a href="#rid50">
          50
         </a>
         ]. Levodopa and anticholinergic drugs may provide modest relief of parkinsonian symptoms.
        </p>
        <p class="headingAnchor" id="H450517892">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/140090.html" rel="external">
          "Society guideline links: Huntington disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H357217">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neuroanatomy
         </strong>
         – The basal ganglia are a complex of deep nuclei that consist of the corpus striatum, globus pallidus, and substantia nigra. These nuclei regulate the initiation, scaling, and control of the amplitude and direction of movement. Movement disorders can result from biochemical or structural abnormalities in these structures. (See
         <a class="local">
          'Anatomy of the basal ganglia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Early-onset Parkinson disease
         </strong>
         – Bradykinetic movement disorders are characterized by slowness of movement and consist predominantly of conditions with features of parkinsonism, of which Parkinson disease (PD) is the most prominent example  (
         <a class="graphic graphic_table graphicRef80669" href="/z/d/graphic/80669.html" rel="external">
          table 1
         </a>
         ). Other characteristic motor findings of PD include tremor at rest, rigidity, and gait disturbance. Nonmotor symptoms include olfactory deficit; behavioral, cognitive, and sleep deficits; and dysautonomia. PD typically presents in middle and late life. However, early-onset disease can occur before age 40 years, and a juvenile form presents before age 20. (See
         <a class="local">
          'Parkinson disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Wilson disease
         </strong>
         – Wilson disease (hepatolenticular degeneration) is a treatable cause of juvenile parkinsonism, dystonia, tremor, and other movement disorders. Clinical aspects of Wilson disease are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3626.html" rel="external">
          "Wilson disease: Epidemiology and pathogenesis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83837.html" rel="external">
          "Wilson disease: Clinical manifestations, diagnosis, and natural history"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3591.html" rel="external">
          "Wilson disease: Management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Juvenile Huntington disease
         </strong>
         – Huntington disease (HD) typically presents during the fourth and fifth decades of life; however, onset occurs during childhood or adolescence in approximately 5 to 7 percent of affected patients. Patients with juvenile-onset HD develop dystonia, ataxia, and seizures. Most of them have the akinetic-rigid syndrome termed the "Westphal variant." Approximately one-fourth have the classic feature of chorea seen in adults. Children also have more rapidly progressive disease than adults. (See
         <a class="local">
          'Juvenile Huntington disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neurodegeneration with brain iron accumulation
         </strong>
         – Neurodegeneration with brain iron accumulation (NBIA) is a rare progressive neurodegenerative syndrome that causes parkinsonism, dystonia, cognitive decline, and other neurologic deficits. NBIA is now considered a spectrum of phenotypically overlapping disorders, with several subtypes defined by differences at the molecular genetic level, including the following (see
         <a class="local">
          'Neurodegeneration with brain iron accumulation'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pantothenate kinase-associated neurodegeneration (PKAN)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Infantile neuroaxonal dystrophy (INAD)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Mitochondrial membrane protein-associated neurodegeneration (MPAN)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Beta-propeller protein-associated neurodegeneration (BPAN)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fatty acid hydroxylase-associated neurodegeneration (FAHN)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Kufor-Rakeb syndrome
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Neuroferritinopathy
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Aceruloplasminemia
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Woodhouse-Sakati syndrome
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         NBIA of unknown cause
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Jankovic J, Lang AE. Diagnosis and Assessment of Parkinson’s Disease and Other Movement disorders. In: Bradley’s Neurology in Clinical Practice, 7th ed, Daroff RB, Jankovic J, Maziotta J, Pomeroy S (Eds), Butterworth-Heinemann (Elsevier), Philadelphia 2016. p.223.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Primers 2017; 3:17013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niemann N, Jankovic J. Juvenile parkinsonism: Differential diagnosis, genetics, and treatment. Parkinsonism Relat Disord 2019; 67:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehanna R, Jankovic J. Young-onset Parkinson's disease: Its unique features and their impact on quality of life. Parkinsonism Relat Disord 2019; 65:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jankovic J. Treatment of hyperkinetic movement disorders. Lancet Neurol 2009; 8:844.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Squitieri F, Jankovic J. Huntington's disease: how intermediate are intermediate repeat lengths? Mov Disord 2012; 27:1714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakels HS, Roos RAC, van Roon-Mom WMC, de Bot ST. Juvenile-Onset Huntington Disease Pathophysiology and Neurodevelopment: A Review. Mov Disord 2022; 37:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fusilli C, Migliore S, Mazza T, et al. Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis. Lancet Neurol 2018; 17:986.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maat-Kievit A, Losekoot M, Zwinderman K, et al. Predictability of age at onset in Huntington disease in the Dutch population. Medicine (Baltimore) 2002; 81:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Testa CM, Jankovic J. Huntington disease: A quarter century of progress since the gene discovery. J Neurol Sci 2019; 396:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother 2016; 17:2461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frank S, Jankovic J. Advances in the pharmacological management of Huntington's disease. Drugs 2010; 70:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wild EJ, Tabrizi SJ. Targets for future clinical trials in Huntington's disease: what's in the pipeline? Mov Disord 2014; 29:1434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wyant KJ, Ridder AJ, Dayalu P. Huntington's Disease-Update on Treatments. Curr Neurol Neurosci Rep 2017; 17:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kordasiewicz HB, Stanek LM, Wancewicz EV, et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 2012; 74:1031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNeill A, Birchall D, Hayflick SJ, et al. T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology 2008; 70:1614.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneider SA, Hardy J, Bhatia KP. Syndromes of neurodegeneration with brain iron accumulation (NBIA): an update on clinical presentations, histological and genetic underpinnings, and treatment considerations. Mov Disord 2012; 27:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walker RH, Jung HH, Dobson-Stone C, et al. Neurologic phenotypes associated with acanthocytosis. Neurology 2007; 68:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneider SA, Dusek P, Hardy J, et al. Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA). Curr Neuropharmacol 2013; 11:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hogarth P, Kurian MA, Gregory A, et al. Consensus clinical management guideline for pantothenate kinase-associated neurodegeneration (PKAN). Mol Genet Metab 2017; 120:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dusek P, Jankovic J, Le W. Iron dysregulation in movement disorders. Neurobiol Dis 2012; 46:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou B, Westaway SK, Levinson B, et al. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 2001; 28:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schulte EC, Claussen MC, Jochim A, et al. Mitochondrial membrane protein associated neurodegenration: a novel variant of neurodegeneration with brain iron accumulation. Mov Disord 2013; 28:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hartig MB, Iuso A, Haack T, et al. Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation. Am J Hum Genet 2011; 89:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hogarth P, Gregory A, Kruer MC, et al. New NBIA subtype: genetic, clinical, pathologic, and radiographic features of MPAN. Neurology 2013; 80:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dezfouli MA, Alavi A, Rohani M, et al. PANK2 and C19orf12 mutations are common causes of neurodegeneration with brain iron accumulation. Mov Disord 2013; 28:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Angelini C, Durand CM, Fergelot P, et al. Autosomal Dominant MPAN: Mosaicism Expands the Clinical Spectrum to Atypical Late-Onset Phenotypes. Mov Disord 2023; 38:2103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayflick SJ, Kruer MC, Gregory A, et al. β-Propeller protein-associated neurodegeneration: a new X-linked dominant disorder with brain iron accumulation. Brain 2013; 136:1708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haack TB, Hogarth P, Kruer MC, et al. Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA. Am J Hum Genet 2012; 91:1144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kimura Y, Sato N, Sugai K, et al. MRI, MR spectroscopy, and diffusion tensor imaging findings in patient with static encephalopathy of childhood with neurodegeneration in adulthood (SENDA). Brain Dev 2013; 35:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saitsu H, Nishimura T, Muramatsu K, et al. De novo mutations in the autophagy gene WDR45 cause static encephalopathy of childhood with neurodegeneration in adulthood. Nat Genet 2013; 45:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kruer MC, Paisán-Ruiz C, Boddaert N, et al. Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA). Ann Neurol 2010; 68:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams DR, Hadeed A, al-Din AS, et al. Kufor Rakeb disease: autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia. Mov Disord 2005; 20:1264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lees AJ, Singleton AB. Clinical heterogeneity of ATP13A2 linked disease (Kufor-Rakeb) justifies a PARK designation. Neurology 2007; 68:1553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Behrens MI, Brüggemann N, Chana P, et al. Clinical spectrum of Kufor-Rakeb syndrome in the Chilean kindred with ATP13A2 mutations. Mov Disord 2010; 25:1929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chinnery PF, Crompton DE, Birchall D, et al. Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain 2007; 130:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levi S, Cozzi A, Arosio P. Neuroferritinopathy: a neurodegenerative disorder associated with L-ferritin mutation. Best Pract Res Clin Haematol 2005; 18:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris ZL, Takahashi Y, Miyajima H, et al. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci U S A 1995; 92:2539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morita H, Ikeda S, Yamamoto K, et al. Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopathological study of a Japanese family. Ann Neurol 1995; 37:646.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woodhouse NJ, Sakati NA. A syndrome of hypogonadism, alopecia, diabetes mellitus, mental retardation, deafness, and ECG abnormalities. J Med Genet 1983; 20:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alazami AM, Al-Saif A, Al-Semari A, et al. Mutations in C2orf37, encoding a nucleolar protein, cause hypogonadism, alopecia, diabetes mellitus, mental retardation, and extrapyramidal syndrome. Am J Hum Genet 2008; 83:684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer E, Kurian MA, Hayflick SJ. Neurodegeneration with Brain Iron Accumulation: Genetic Diversity and Pathophysiological Mechanisms. Annu Rev Genomics Hum Genet 2015; 16:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pellecchia MT, Valente EM, Cif L, et al. The diverse phenotype and genotype of pantothenate kinase-associated neurodegeneration. Neurology 2005; 64:1810.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayflick SJ, Westaway SK, Levinson B, et al. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med 2003; 348:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stamelou M, Lai SC, Aggarwal A, et al. Dystonic opisthotonus: a "red flag" for neurodegeneration with brain iron accumulation syndromes? Mov Disord 2013; 28:1325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiapparini L, Savoiardo M, D'Arrigo S, et al. The "eye-of-the-tiger" sign may be absent in the early stages of classic pantothenate kinase associated neurodegeneration. Neuropediatrics 2011; 42:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kruer MC, Boddaert N, Schneider SA, et al. Neuroimaging features of neurodegeneration with brain iron accumulation. AJNR Am J Neuroradiol 2012; 33:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneider SA. Neurodegeneration with Brain Iron Accumulation. Curr Neurol Neurosci Rep 2016; 16:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klopstock T, Tricta F, Neumayr L, et al. Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study. Lancet Neurol 2019; 18:631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klopstock T, Videnovic A, Bischoff AT, et al. Fosmetpantotenate Randomized Controlled Trial in Pantothenate Kinase-Associated Neurodegeneration. Mov Disord 2021; 36:1342.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6231 Version 25.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Jankovic J, Lang AE. Diagnosis and Assessment of Parkinson’s Disease and Other Movement disorders. In: Bradley’s Neurology in Clinical Practice, 7th ed, Daroff RB, Jankovic J, Maziotta J, Pomeroy S (Eds), Butterworth-Heinemann (Elsevier), Philadelphia 2016. p.223.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28332488" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Parkinson disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31272925" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Juvenile parkinsonism: Differential diagnosis, genetics, and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31176633" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Young-onset Parkinson's disease: Its unique features and their impact on quality of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19679276" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Treatment of hyperkinetic movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23008174" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Huntington's disease: how intermediate are intermediate repeat lengths?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34636452" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Juvenile-Onset Huntington Disease Pathophysiology and Neurodevelopment: A Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30243861" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12169880" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Predictability of age at onset in Huntington disease in the Dutch population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30419368" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Huntington disease: A quarter century of progress since the gene discovery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27819145" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Dopamine depleters in the treatment of hyperkinetic movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20329804" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Advances in the pharmacological management of Huntington's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25155142" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Targets for future clinical trials in Huntington's disease: what's in the pipeline?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28324302" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Huntington's Disease-Update on Treatments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22726834" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18443312" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22031173" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Syndromes of neurodegeneration with brain iron accumulation (NBIA): an update on clinical presentations, histological and genetic underpinnings, and treatment considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17210889" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Neurologic phenotypes associated with acanthocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23814539" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28034613" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Consensus clinical management guideline for pantothenate kinase-associated neurodegeneration (PKAN).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22266337" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Iron dysregulation in movement disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11479594" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23436634" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Mitochondrial membrane protein associated neurodegenration: a novel variant of neurodegeneration with brain iron accumulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21981780" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23269600" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : New NBIA subtype: genetic, clinical, pathologic, and radiographic features of MPAN.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23166001" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : PANK2 and C19orf12 mutations are common causes of neurodegeneration with brain iron accumulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37605305" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Autosomal Dominant MPAN: Mosaicism Expands the Clinical Spectrum to Atypical Late-Onset Phenotypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23687123" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : β-Propeller protein-associated neurodegeneration: a new X-linked dominant disorder with brain iron accumulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23176820" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22892189" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : MRI, MR spectroscopy, and diffusion tensor imaging findings in patient with static encephalopathy of childhood with neurodegeneration in adulthood (SENDA).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23435086" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : De novo mutations in the autophagy gene WDR45 cause static encephalopathy of childhood with neurodegeneration in adulthood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20853438" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15986421" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Kufor Rakeb disease: autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17485640" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Clinical heterogeneity of ATP13A2 linked disease (Kufor-Rakeb) justifies a PARK designation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20683840" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Clinical spectrum of Kufor-Rakeb syndrome in the Chilean kindred with ATP13A2 mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17142829" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15737889" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Neuroferritinopathy: a neurodegenerative disorder associated with L-ferritin mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7708681" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Aceruloplasminemia: molecular characterization of this disorder of iron metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7755360" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopathological study of a Japanese family.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6876115" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : A syndrome of hypogonadism, alopecia, diabetes mellitus, mental retardation, deafness, and ECG abnormalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19026396" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Mutations in C2orf37, encoding a nucleolar protein, cause hypogonadism, alopecia, diabetes mellitus, mental retardation, and extrapyramidal syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25973518" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Neurodegeneration with Brain Iron Accumulation: Genetic Diversity and Pathophysiological Mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15911822" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The diverse phenotype and genotype of pantothenate kinase-associated neurodegeneration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12510040" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23736975" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Dystonic opisthotonus: a "red flag" for neurodegeneration with brain iron accumulation syndromes?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21877312" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The "eye-of-the-tiger" sign may be absent in the early stages of classic pantothenate kinase associated neurodegeneration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21920862" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Neuroimaging features of neurodegeneration with brain iron accumulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26739693" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Neurodegeneration with Brain Iron Accumulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31202468" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33200489" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Fosmetpantotenate Randomized Controlled Trial in Pantothenate Kinase-Associated Neurodegeneration.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
